EUVIMEDEUVIMED entdecken
Crossref

Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics

Miki Yamada, Hiromitsu Jinno, Saki Naruse, Yuka Isono, Yuka Maeda, Ayana Sato, Akiko Matsumoto, Tatsuhiko Ikeda, Masahiro Sugimoto

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07370-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Miki Yamada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Metabolomics. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Preoperative chemotherapy is a critical component of breast cancer management, yet its effectiveness is not uniform. Moreover, the adverse effects associated with chemotherapy necessitate the identification of a patient subgroup that would derive the maximum benefit from this treatment. This study aimed to establish a method for predicting the response to neoadjuvant chemotherapy in breast cancer patients utilizing a metabolomic approach. METHODS: Plasma samples were obtained from 87 breast cancer patients undergoing neoadjuvant chemotherapy at our facility, collected both before the commencement of the treatment and before the second treatment cycle. Metabolite analysis was conducted using capillary electrophoresis-mass spectrometry (CE-MS) and liquid chromatography-mass spectrometry (LC-MS). We performed comparative profiling of metabolite concentrations by assessing the metabolite profiles of patients who achieved a pathological complete response (pCR) against those who did not, both in initial and subsequent treatment cycles. RESULTS: Significant variances were observed in the metabolite profiles between pCR and non-pCR cases, both at the onset of preoperative chemotherapy and before the second cycle. Noteworthy distinctions were also evident between the metabolite profiles from the initial and the second neoadjuvant chemotherapy courses. Furthermore, metabolite profiles exhibited variations associated with intrinsic subtypes at all assessed time points. CONCLUSION: The application of plasma metabolomics, utilizing CE-MS and LC-MS, may serve as a tool for predicting the efficacy of neoadjuvant chemotherapy in breast cancer in the future after all necessary validations have been completed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyMetabolomicsHumansFemaleMiddle AgedAdultAgedTreatment OutcomeMetabolomeChromatography, LiquidMass SpectrometryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorPrognosisElectrophoresis, CapillaryChemotherapy, Adjuvant

Stichwörter der Autor:innen

Breast cancerCapillary electrophoresis-mass spectrometry (CE-MS)Liquid chromatography-mass spectrometry (LC–MS)MetabolomicsNeoadjuvant chemotherapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606, Japan.
  • Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606, Japan. jinno@med.teikyo-u.ac.jp.
  • Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, 997-0052, Japan.
  • Institute of Medical Science, Tokyo Medical University, Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Förderung

  • KAKENHI

Zitieren

APA

Yamada, M., Jinno, H., Naruse, S., Isono, Y., Maeda, Y., Sato, A., Matsumoto, A., Ikeda, T., & Sugimoto, M. (2024). Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07370-2

Vancouver

Yamada M, Jinno H, Naruse S, Isono Y, Maeda Y, Sato A, et al. Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07370-2

BibTeX
@article{Yamada2024,
  author = {Yamada, Miki and Jinno, Hiromitsu and Naruse, Saki and Isono, Yuka and Maeda, Yuka and Sato, Ayana and Matsumoto, Akiko and Ikeda, Tatsuhiko and Sugimoto, Masahiro},
  title = {Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07370-2}
}
Kostenlos starten →